PE20120081A1 - Derivados de 6-tert-butil-8-fluor-2-(2-hidroximetil-3-{1-metil-5-piridin-2-il-amino-6-oxo-1,6-dihidro-piridin-3-il}-fenil)-ftalazin-1-ona como inhibidores de la tirosina-quinasa de bruton - Google Patents
Derivados de 6-tert-butil-8-fluor-2-(2-hidroximetil-3-{1-metil-5-piridin-2-il-amino-6-oxo-1,6-dihidro-piridin-3-il}-fenil)-ftalazin-1-ona como inhibidores de la tirosina-quinasa de brutonInfo
- Publication number
- PE20120081A1 PE20120081A1 PE2011001551A PE2011001551A PE20120081A1 PE 20120081 A1 PE20120081 A1 PE 20120081A1 PE 2011001551 A PE2011001551 A PE 2011001551A PE 2011001551 A PE2011001551 A PE 2011001551A PE 20120081 A1 PE20120081 A1 PE 20120081A1
- Authority
- PE
- Peru
- Prior art keywords
- pyridin
- methyl
- halogen
- hydroximethyl
- ona
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Abstract
SE REFIERE A COMPUESTOS HETEROCICLICOS DE FORMULA (A) DONDE R ES H, -R1, -R1-R2-R3, ENTRE OTROS, EN DONDE R1 ES ARILO, HETEROARILO, CICLOALQUILO, ENTRE OTROS; R2 ES -C(=O), -NHC(=O)O, -S(=O)2, ENTRE OTROS; R3 ES H O R4, EN DONDE R4 ES ALQUILO INFERIOR, ALCOXI INFERIOR, AMINO, ENTRE OTROS; X Y X' SON CADA UNO CH O N; Y1 ES H, ALQUILO INFERIOR O HALOALQUILO INFERIOR; Y2' E Y2 SON CADA UNO HALOGENO, OXIMA O ALQUILO INFERIOR OPCIONALMENTE SUSTITUIDO CON HIDROXI, ALCOXI INFERIOR, HALOGENO, ENTRE OTROS; n ES DE 0 A 2; Z* ES UN COMPUESTO DE FORMULA (Ia), (IIa), ENTRE OTROS, EN DONDE Y3 ES H, HALOGENO O ALQUILO INFERIOR; m ES 0 A 1; Y5 ES HALOGENO, HIDROXI, ALQUILO INFERIOR, ENTRE OTROS; Y4 ES Y4a, Y4b, ENTRE OTROS, EN DONDE Y4a ES H O HALOGENO; Y4b ES ALQUILO INFERIOR OPCIONALMENTE SUSTITUIDO. SON COMPUESTOS PREFERIDOS: 2-(3-{5-[5-(1-AMINO-1-METIL-ETIL)-PIRIDIN-2-ILAMINO]-1-METIL-6-OXO-1,6-DIHIDRO-PIRIDIN-3-IL}-2-HIDROXIMETIL-FENIL)-6-TERT-BUTIL-8-FLUOR-2H-FTALAZIN-1-ONA; 6-TERT-BUTIL-2-(3-{5-[5-(1-ETILAMINO-1-METIL-ETIL)-PIRIDIN-2-ILAMINO]-1-METIL-6-OXO-1,6-DIHIDRO-PIRIDIN-3-IL}-2-HIDROXIMETIL-FENIL)-8-FLUOR-2H-FTALAZIN-1-ONA; ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA TIROSINA QUINASA DE BRUTON (Btk) SIENDO UTILES EN EL TRATAMIENTO DE ARTRITIS REUMATOIDE, PSORIASIS, ASMA
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20902109P | 2009-03-02 | 2009-03-02 | |
US30006410P | 2010-02-01 | 2010-02-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20120081A1 true PE20120081A1 (es) | 2012-02-06 |
Family
ID=42097405
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2015001561A PE20151336A1 (es) | 2009-03-02 | 2010-02-25 | Inhibidores de la tirosina-quinasa de bruton |
PE2011001551A PE20120081A1 (es) | 2009-03-02 | 2010-02-25 | Derivados de 6-tert-butil-8-fluor-2-(2-hidroximetil-3-{1-metil-5-piridin-2-il-amino-6-oxo-1,6-dihidro-piridin-3-il}-fenil)-ftalazin-1-ona como inhibidores de la tirosina-quinasa de bruton |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2015001561A PE20151336A1 (es) | 2009-03-02 | 2010-02-25 | Inhibidores de la tirosina-quinasa de bruton |
Country Status (20)
Country | Link |
---|---|
US (1) | US8299077B2 (es) |
EP (1) | EP2403846B1 (es) |
JP (1) | JP5512707B2 (es) |
KR (1) | KR101347978B1 (es) |
CN (2) | CN102341383B (es) |
AR (1) | AR076066A1 (es) |
AU (1) | AU2010220435B2 (es) |
BR (1) | BRPI1009112A2 (es) |
CA (1) | CA2753341C (es) |
CL (1) | CL2011002115A1 (es) |
ES (1) | ES2607644T3 (es) |
HK (2) | HK1164859A1 (es) |
IL (1) | IL214351A0 (es) |
MX (1) | MX339583B (es) |
PE (2) | PE20151336A1 (es) |
RU (1) | RU2542585C2 (es) |
SG (1) | SG173816A1 (es) |
TW (2) | TWI519529B (es) |
WO (1) | WO2010100070A1 (es) |
ZA (1) | ZA201301679B (es) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8258134B2 (en) * | 2008-04-16 | 2012-09-04 | Hoffmann-La Roche Inc. | Pyridazinone glucokinase activators |
PE20110164A1 (es) * | 2008-07-02 | 2011-03-28 | Hoffmann La Roche | Nuevas fenilpirazinonas como inhibidores de quinasa |
JP5369183B2 (ja) | 2008-07-16 | 2013-12-18 | ファーマサイクリックス,インク. | 固形腫瘍の治療用のブルートンのチロシンキナーゼの阻害剤 |
MX2011009824A (es) | 2009-03-23 | 2012-01-25 | Glenmark Pharmaceuticals Sa | Derivados de pirimidina-diona fusionados como moduladores del trpa1. |
CA2800913C (en) | 2010-06-03 | 2019-07-23 | Pharmacyclics, Inc. | The use of inhibitors of bruton's tyrosine kinase (btk) |
AR082590A1 (es) * | 2010-08-12 | 2012-12-19 | Hoffmann La Roche | Inhibidores de la tirosina-quinasa de bruton |
WO2012030990A1 (en) * | 2010-09-01 | 2012-03-08 | Gilead Connecticut, Inc. | Pyridazinones, method of making, and method of use thereof |
KR101837223B1 (ko) | 2010-09-01 | 2018-03-09 | 질레드 코네티컷 인코포레이티드 | 피리디논/피라지논, 그의 제조 방법 및 사용 방법 |
CN103582637B (zh) | 2011-05-17 | 2015-08-12 | 弗·哈夫曼-拉罗切有限公司 | 酪氨酸激酶抑制剂 |
EP2726077A4 (en) * | 2011-06-28 | 2014-12-10 | Pharmacyclics Inc | METHODS AND COMPOSITIONS FOR INHIBITING BONE RESORPTION |
US9138436B2 (en) | 2011-07-13 | 2015-09-22 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
EP2744804B1 (en) * | 2011-08-17 | 2017-05-17 | F. Hoffmann-La Roche AG | Inhibitors of bruton's tyrosine kinase |
KR102258778B1 (ko) * | 2011-10-19 | 2021-06-02 | 파마싸이클릭스 엘엘씨 | 브루톤 티로신 인산화효소(btk)의 억제제의 용도 |
JP5976826B2 (ja) * | 2011-11-03 | 2016-08-24 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Btk活性阻害剤としての8−フルオロフタラジン−1(2h)−オン化合物 |
AU2012332368A1 (en) * | 2011-11-03 | 2014-05-22 | F. Hoffmann-La Roche Ag | Alkylated piperazine compounds as inhibitors of Btk activity |
UA111756C2 (uk) * | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
JP5832664B2 (ja) * | 2011-12-09 | 2015-12-16 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ブルトン型チロシンキナーゼの阻害剤 |
WO2013157021A1 (en) | 2012-04-20 | 2013-10-24 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
CN104662018B (zh) | 2012-04-20 | 2017-10-24 | 阿迪维纳斯治疗有限公司 | 取代的杂双环化合物、组合物及其医疗应用 |
BR112015001690A2 (pt) | 2012-07-24 | 2017-11-07 | Pharmacyclics Inc | mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk) |
JP6348492B2 (ja) | 2012-08-10 | 2018-06-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ブルトン型チロシンキナーゼ(btk)阻害剤としてのヘテロ芳香族化合物 |
KR20150054994A (ko) | 2012-09-13 | 2015-05-20 | 에프. 호프만-라 로슈 아게 | 브루톤 티로신 키나아제의 억제제 |
RU2015120216A (ru) * | 2012-11-16 | 2017-01-10 | Ф. Хоффманн-Ля Рош Аг | Ингибиторы тирозинкиназы брутона |
WO2014083026A1 (en) * | 2012-11-30 | 2014-06-05 | F. Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
US9556147B2 (en) * | 2013-03-05 | 2017-01-31 | Hoffmann-La Inc. | Inhibitors of bruton's tyrosine kinase |
KR101763504B1 (ko) * | 2013-03-05 | 2017-07-31 | 에프. 호프만-라 로슈 아게 | 브루톤 티로신 키나아제의 억제제 |
JP2016519684A (ja) | 2013-04-08 | 2016-07-07 | デニス エム ブラウン | 準最適に投与された薬物療法の有効性を改善するための及び/又は副作用を低減するための方法および組成物 |
HUE031980T2 (en) | 2013-04-25 | 2017-08-28 | Beigene Ltd | Condensed heterocyclic compounds as protein kinase inhibitors |
CN104177338B (zh) * | 2013-05-22 | 2018-04-03 | 南京勇山生物科技有限公司 | 一类布鲁顿激酶抑制剂 |
CN104211703B (zh) * | 2013-05-30 | 2018-04-03 | 南京勇山生物科技有限公司 | 一类作为布鲁顿激酶抑制剂的稠杂环化合物 |
EP3016943B1 (en) * | 2013-07-03 | 2019-08-21 | F. Hoffmann-La Roche AG | Heteroaryl pyridone and aza-pyridone amide compounds |
US9993460B2 (en) | 2013-07-26 | 2018-06-12 | Race Oncology Ltd. | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof |
CN105683178B (zh) * | 2013-07-26 | 2019-04-12 | 卡尔那生物科学株式会社 | 三嗪衍生物 |
US9415050B2 (en) | 2013-08-12 | 2016-08-16 | Pharmacyclics Llc | Methods for the treatment of HER2 amplified cancer |
HUE049281T2 (hu) | 2013-09-13 | 2020-09-28 | Beigene Switzerland Gmbh | Anti-PD1 antitestek, valamint terapeutikumként és diagnosztikumként történõ alkalmazásuk |
US9512084B2 (en) * | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
JP6275846B2 (ja) * | 2013-12-05 | 2018-02-07 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 求電子性官能基を有するヘテロアリールピリドン及びアザ−ピリドン化合物 |
MX2016006351A (es) * | 2013-12-13 | 2016-08-01 | Hoffmann La Roche | Inhibidores de tirosina cinasa de bruton. |
US9885086B2 (en) | 2014-03-20 | 2018-02-06 | Pharmacyclics Llc | Phospholipase C gamma 2 and resistance associated mutations |
WO2016000619A1 (en) | 2014-07-03 | 2016-01-07 | Beigene, Ltd. | Anti-pd-l1 antibodies and their use as therapeutics and diagnostics |
CN106922146B (zh) * | 2014-10-02 | 2020-05-26 | 豪夫迈·罗氏有限公司 | 用于治疗由布鲁顿酪氨酸激酶(btk)介导的疾病的吡唑甲酰胺化合物 |
CN104402828A (zh) * | 2014-11-05 | 2015-03-11 | 定陶县友帮化工有限公司 | 一种3-氨基-4-溴-6-氯哒嗪的合成方法 |
TW201702218A (zh) | 2014-12-12 | 2017-01-16 | 美國杰克森實驗室 | 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法 |
EP3042903B1 (en) | 2015-01-06 | 2019-08-14 | Impetis Biosciences Ltd. | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
LT3317281T (lt) | 2015-07-02 | 2020-07-27 | Acerta Pharma B.V. | (s)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benzamido kompozicijų kietosios formos |
RU2608128C1 (ru) * | 2015-11-12 | 2017-01-13 | федеральное государственное бюджетное образовательное учреждение высшего образования "Ростовский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РостГМУ Минздрава России) | Способ лечения больных с х-сцепленной агаммаглобулинемией |
EP3402789B1 (en) * | 2016-01-13 | 2020-03-18 | Boehringer Ingelheim International Gmbh | Isoquinolones as btk inhibitors |
CA3028824C (en) * | 2016-06-22 | 2023-12-12 | Shanghai Fochon Pharmaceutical Co., Ltd. | Substituted pyrrolo[2,3-d]pyridazin-4-ones and pyrazolo[3,4-d]pyridazin-4-ones as protein kinase inhibitors |
EP3481393B1 (en) | 2016-07-05 | 2021-04-14 | Beigene, Ltd. | Combination of a pd-1 antagonist and a raf inhibitor for treating cancer |
MX2019000884A (es) | 2016-07-21 | 2019-09-04 | Biogen Ma Inc | Formas de succinato y composiciones de inhibidores de la tirosina cinasa de bruton. |
TW202233628A (zh) | 2016-08-16 | 2022-09-01 | 英屬開曼群島商百濟神州有限公司 | (s)-7-(1-丙烯醯基六氫吡啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氫吡唑並[1,5-a]嘧啶-3-甲醯胺的晶型、其製備和用途 |
FI3500299T3 (fi) | 2016-08-19 | 2024-02-14 | Beigene Switzerland Gmbh | Tsanubrutinibin yhdistelmä cd20-tai pd-1-vasta-aineen kanssa käytettäväksi syövän hoidossa |
MA46285A (fr) | 2016-09-19 | 2019-07-31 | Mei Pharma Inc | Polythérapie |
CN110023313B (zh) | 2016-12-02 | 2022-10-25 | 豪夫迈·罗氏有限公司 | 二环酰胺化合物及其使用方法 |
AU2017368331A1 (en) | 2016-12-03 | 2019-06-13 | Acerta Pharma B.V. | Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors |
US11555038B2 (en) | 2017-01-25 | 2023-01-17 | Beigene, Ltd. | Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
US11597768B2 (en) | 2017-06-26 | 2023-03-07 | Beigene, Ltd. | Immunotherapy for hepatocellular carcinoma |
KR20200030558A (ko) | 2017-07-14 | 2020-03-20 | 에프. 호프만-라 로슈 아게 | 이환형 케톤 화합물 및 이의 사용 방법 |
WO2019034009A1 (en) | 2017-08-12 | 2019-02-21 | Beigene, Ltd. | BTK INHIBITOR WITH ENHANCED DOUBLE SELECTIVITY |
KR102613433B1 (ko) | 2017-10-11 | 2023-12-13 | 주식회사 대웅제약 | 신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물 |
MA50503A (fr) | 2017-10-31 | 2020-09-09 | Hoffmann La Roche | Sulfones et sulfoxydes bicycliques et procédés d'utilisation associés |
US11786529B2 (en) | 2017-11-29 | 2023-10-17 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors |
AU2018388404B2 (en) | 2017-12-22 | 2023-11-02 | HiberCell Inc. | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
CN111961035B (zh) * | 2019-05-20 | 2022-11-01 | 南京科技职业学院 | 一类含有羟基异喹啉类结构的化合物、药物组合物以及其应用 |
WO2023152888A1 (ja) * | 2022-02-10 | 2023-08-17 | カルナバイオサイエンス株式会社 | フルオロイソキノリン化合物およびその製造法 |
US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003270489A1 (en) | 2002-09-09 | 2004-03-29 | Cellular Genomics, Inc. | 6-ARYL-IMIDAZO(1,2-a)PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF |
US7405295B2 (en) | 2003-06-04 | 2008-07-29 | Cgi Pharmaceuticals, Inc. | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
EP1831174B1 (en) * | 2004-12-24 | 2011-03-02 | AstraZeneca AB | Amide derivatives |
AR063706A1 (es) | 2006-09-11 | 2009-02-11 | Cgi Pharmaceuticals Inc | Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden. |
AR063707A1 (es) | 2006-09-11 | 2009-02-11 | Cgi Pharmaceuticals Inc | Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmacéuticas que las comprenden. |
WO2009053269A1 (en) | 2007-10-23 | 2009-04-30 | F. Hoffmann-La Roche Ag | Novel kinase inhibitors |
ES2462642T3 (es) | 2007-12-14 | 2014-05-26 | F. Hoffmann-La Roche Ag | Nuevos derivados de imidazo[1,2-a]piridina e imidazo[1,2-b]piridazina |
NZ586916A (en) * | 2008-02-05 | 2012-06-29 | Hoffmann La Roche | Novel pyridinones and pyridazinones |
US7683064B2 (en) | 2008-02-05 | 2010-03-23 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
CA2728016C (en) | 2008-06-24 | 2017-02-28 | F. Hoffmann-La Roche Ag | Novel substituted pyridin-2-ones and pyridazin-3-ones |
PE20110164A1 (es) * | 2008-07-02 | 2011-03-28 | Hoffmann La Roche | Nuevas fenilpirazinonas como inhibidores de quinasa |
-
2010
- 2010-02-24 US US12/711,312 patent/US8299077B2/en not_active Expired - Fee Related
- 2010-02-25 PE PE2015001561A patent/PE20151336A1/es not_active Application Discontinuation
- 2010-02-25 CN CN201080010268.3A patent/CN102341383B/zh not_active Expired - Fee Related
- 2010-02-25 KR KR1020117020555A patent/KR101347978B1/ko not_active IP Right Cessation
- 2010-02-25 ES ES10705373.8T patent/ES2607644T3/es active Active
- 2010-02-25 WO PCT/EP2010/052394 patent/WO2010100070A1/en active Application Filing
- 2010-02-25 JP JP2011552393A patent/JP5512707B2/ja not_active Expired - Fee Related
- 2010-02-25 EP EP10705373.8A patent/EP2403846B1/en not_active Not-in-force
- 2010-02-25 CA CA2753341A patent/CA2753341C/en not_active Expired - Fee Related
- 2010-02-25 BR BRPI1009112A patent/BRPI1009112A2/pt not_active IP Right Cessation
- 2010-02-25 RU RU2011140064/04A patent/RU2542585C2/ru not_active IP Right Cessation
- 2010-02-25 AU AU2010220435A patent/AU2010220435B2/en not_active Ceased
- 2010-02-25 PE PE2011001551A patent/PE20120081A1/es not_active Application Discontinuation
- 2010-02-25 MX MX2011008643A patent/MX339583B/es active IP Right Grant
- 2010-02-25 SG SG2011060654A patent/SG173816A1/en unknown
- 2010-02-25 CN CN201510400556.4A patent/CN105001206A/zh active Pending
- 2010-03-01 AR ARP100100592A patent/AR076066A1/es unknown
- 2010-03-01 TW TW099105838A patent/TWI519529B/zh not_active IP Right Cessation
- 2010-03-01 TW TW103123368A patent/TW201439080A/zh unknown
-
2011
- 2011-07-28 IL IL214351A patent/IL214351A0/en not_active IP Right Cessation
- 2011-08-30 CL CL2011002115A patent/CL2011002115A1/es unknown
-
2012
- 2012-06-07 HK HK12105531.1A patent/HK1164859A1/xx not_active IP Right Cessation
-
2013
- 2013-03-05 ZA ZA2013/01679A patent/ZA201301679B/en unknown
-
2016
- 2016-04-26 HK HK16104764.8A patent/HK1216887A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
BRPI1009112A2 (pt) | 2016-03-01 |
MX339583B (es) | 2016-06-01 |
JP2012519200A (ja) | 2012-08-23 |
PE20151336A1 (es) | 2015-09-18 |
KR20110111325A (ko) | 2011-10-10 |
MX2011008643A (es) | 2011-09-06 |
CN102341383B (zh) | 2015-09-16 |
AU2010220435B2 (en) | 2015-12-24 |
EP2403846B1 (en) | 2016-11-02 |
CN105001206A (zh) | 2015-10-28 |
RU2542585C2 (ru) | 2015-02-20 |
HK1164859A1 (en) | 2012-09-28 |
ZA201301679B (en) | 2015-06-24 |
TWI519529B (zh) | 2016-02-01 |
AR076066A1 (es) | 2011-05-18 |
HK1216887A1 (zh) | 2016-12-09 |
CA2753341A1 (en) | 2010-09-10 |
WO2010100070A1 (en) | 2010-09-10 |
RU2011140064A (ru) | 2013-04-10 |
US20100222325A1 (en) | 2010-09-02 |
ES2607644T3 (es) | 2017-04-03 |
AU2010220435A1 (en) | 2011-08-18 |
KR101347978B1 (ko) | 2014-01-14 |
CA2753341C (en) | 2017-02-21 |
TW201035072A (en) | 2010-10-01 |
CL2011002115A1 (es) | 2012-03-30 |
EP2403846A1 (en) | 2012-01-11 |
JP5512707B2 (ja) | 2014-06-04 |
CN102341383A (zh) | 2012-02-01 |
SG173816A1 (en) | 2011-09-29 |
US8299077B2 (en) | 2012-10-30 |
TW201439080A (zh) | 2014-10-16 |
IL214351A0 (en) | 2011-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20120081A1 (es) | Derivados de 6-tert-butil-8-fluor-2-(2-hidroximetil-3-{1-metil-5-piridin-2-il-amino-6-oxo-1,6-dihidro-piridin-3-il}-fenil)-ftalazin-1-ona como inhibidores de la tirosina-quinasa de bruton | |
PE20090775A1 (es) | Nuevos derivados de biarilo | |
PE20140865A1 (es) | Inhibidores de la tirosina-quinasa de bruton | |
PE20121500A1 (es) | 2-amino-5,5-difluor-5,6-dihidro-4h-oxazinas como inhibidores de bace 1 y/o bace 2 | |
PE20141004A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
PE20131153A1 (es) | Inhibidores de la tirosina-quinasa de bruton | |
PE20130279A1 (es) | Compuestos heteroarilo nitrogenados | |
PE20141203A1 (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
PE20141005A1 (es) | 1,3-oxazinas como inhibidores de bace1 y/o bace2 | |
PE20141120A1 (es) | Compuestos heterociclicos | |
PE20080205A1 (es) | DERIVADOS DE PIRAZOLOPIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE LA TIROSIN QUINASA Tie2 | |
PE20090183A1 (es) | Derivados de 1-oxa-3,9-diaza-espiro-[5.5]undecan-2-ona como moduladores de ccr5 | |
PE20090288A1 (es) | Derivados de quinoxalina como inhibidores de la pi3 quinasa | |
PE20091492A1 (es) | Compuestos y composiciones como inhibidores de c-kit y de la cinasa pdgfr | |
PE20090290A1 (es) | Derivados de pirrolopiridina como inhibidores de bace | |
PE20141308A1 (es) | Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a | |
DK2091948T3 (da) | Nye inhibitorer af glutaminylcyclase | |
PE20150621A1 (es) | Derivados de 2,4-diamino-pirimidina n2, n4-disustituidos como inhibidores de jak3 | |
PE20091734A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
PE20110575A1 (es) | INHIBIDORES DE mTOR CINASA PARA INDICADORES DE ONCOLOGIA Y ENFERMEDADES ASOCIADAS CON LA TRAYECTORIA mTOR/PI3K/AKT | |
PE20130576A1 (es) | Compuestos heterociclicos de nitrogeno utiles como inhibidores de pde10 | |
PE20121148A1 (es) | Compuestos heterociclicos y usos de los mismos | |
PE20121480A1 (es) | Aminopirimidinas como inhibidores de syk | |
PE20120693A1 (es) | Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2) | |
PE20140623A1 (es) | Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |